Skip to main content

Table 1 Details of fractionation regimes used in our study population (n = 115)

From: Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Fractionation regime No. of cases (%)
6000 cGy/20 fractions 30 (26.1%)
5940 cGy/22 fractions 2 (1.7%)
6300 cGy/23 fractions 1 (0.9%)
6000 cGy/24 fractions 1 (0.9%)
6240 cGy/24 fractions 1 (0.9%)
6000 cGy/25 fractions 11 (9.6%)
6100 cGy/25 fractions 1 (0.9%)
6250 cGy/25 fractions 9 (7.8%)
6400 cGy/25 fractions 1 (0.9%)
6500 cGy/25 fractions 1 (0.9%)
7000 cGy/25 fractions 1 (0.9%)
6240 cGy/26 fractions 1 (0.9%)
6210 cGy/27 fractions 4 (3.5%)
6160 cGy/28 fractions 5 (4.3%)
6000 cGy/30 fractions 30 (26.1%)
6400 cGy/32 fractions 8 (7.0%)
6600 cGy/33 fractions 6 (5.2%)
7000 cGy/35 fractions 2 (1.7%)
  1. Note: The prescribed doses were given to gross tumor volume